Introduction
============

Hemorrhagic shock (HS) and subsequent resuscitation result in an overly active systemic immuno-inflammatory response that may produce an exaggerated physiological response, resulting in systemic inflammatory response syndrome (SIRS). Complications of SIRS often involve organ dysfunction and organ failure, including acute lung injury (ALI) and multiple organ dysfunction syndrome (MODS), with high mortality rates, ranging from 27--100% ([@b1-etm-0-0-7757],[@b2-etm-0-0-7757]). Although substantial progress has been made in the treatment of HS, the incidence of SIRS following HS remains up to 43% ([@b3-etm-0-0-7757]), and there is no effective measure to prevent the patients from entering the SIRS-MODS stage.

The 'second hit' model proposed by Moore *et al* ([@b4-etm-0-0-7757]) is considered to be a good standard as an empirical explanation for HS-associated inflammation. HS, the first 'hit' primes the inflammatory system and a second 'hit', for example through infection, aggravates the already sensitized immune system ([@b4-etm-0-0-7757]). Inflammation is governed by interactions between proinflammatory and counter-inflammatory states; the imbalance between pro-inflammatory and anti-inflammatory responses serves a key role in the development of ALI and MODS ([@b5-etm-0-0-7757]), but the exact mechanism of HS sensitization to ALI and SIRS remains unclear. Therefore, it is of vital importance to investigate the mechanisms involved in the inflammatory response state following HS.

Evidence has revealed that the activation of pulmonary vascular endothelial cells (ECs) and EC-mediated inflammation serve important functions in organ injury following a hemorrhage ([@b6-etm-0-0-7757]). The pyrin protein, consisting of 781 amino acid residues, is expressed in neutrophils, monocytes and macrophages, and its expression is regulated by a variety of cytokines ([@b7-etm-0-0-7757]). The pyrin protein is able to inhibit the activation of caspase-1 and inhibit the mature release of interleukin (IL)-1β, a proinflammatory mediator ([@b8-etm-0-0-7757]) that is involved in lung inflammation ([@b9-etm-0-0-7757]). Caspase-1 is also synthesized as an inactive 45 kDa protein (procaspase-1) that undergoes autocatalytic processing following assembly of the inflammasome in response to an appropriate stimulus ([@b10-etm-0-0-7757],[@b11-etm-0-0-7757]). Of the cytokines that are able to regulate the expression of pyrin, interleukin (IL)-10 is able to induce the expression of pyrin protein in macrophages ([@b8-etm-0-0-7757]). It has been demonstrated that the immunosuppressive cytokine IL-10 may inhibit the activation of monocytes/macrophages and decrease the release of cytokines and chemokines induced by lipopolysaccharides (LPS) ([@b9-etm-0-0-7757]). *In vivo* experiments of ischemia/reperfusion have revealed that IL-10 is able to effectively decrease structural organ damage; however, when a IL-10 neutralizing antibody or IL-10 knockout is used, the inflammatory reaction is aggravated ([@b12-etm-0-0-7757]).

Taking into consideration these diverse results, it was hypothesized that pyrin and IL-10 are involved in the regulation of inflammation in pulmonary vascular ECs, and that the decrease in IL-10 expression contributes to a severe inflammatory response.

Materials and methods
=====================

### Animals

Adult female Sprague-Dawley rats (n=100; weight, 200--240 g; Zhejiang Laboratory Animal Center) were provided by the Experimental Animal Center of the First Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang, China). The rats were maintained in a standard cage, in a 22--24°C environment, with a 12:12 h light:dark cycle and *ad libitum* access to food and water. All experiments were performed in accordance with the institutional guidelines for animal care and welfare. The present study was approved by the Medical Ethics Committee of Zheijang Hospital.

### Experimental protocol

Prior to the initiation of the experiment, the rats were fasted for 24 h with *ad libitum* access to water ([@b13-etm-0-0-7757],[@b14-etm-0-0-7757]), in order to avoid backflow and aspiration when the trachea was intubated, and the greatest weight loss observed was 16g (\~7% of body weight). Following the induction of anesthesia with an intraperitoneal injection of 2% sodium pentobarbital solution (50 mg/kg; Westang Biotechenology, Co., Ltd.), the left femoral artery was cannulated with an external infusion device to allow for the monitoring of mean arterial pressure, blood sampling and resuscitation. HS was initiated by the withdrawal of arterial blood and the mean arterial pressure reached 40±5 mmHg within 20 min. Blood was collected into a 10 ml heparinized syringe to prevent the blood from clotting. In order to exclude the effect of heparin on the experimental results, the control group was administered equal amounts of heparin through arterial catheterization. Subsequent to a hypotensive period of 1 h, autologous blood transfusion was performed and the same quantity of lactate solution was administered ([@b15-etm-0-0-7757]). Resuscitation was completed within 20 min. Following resuscitation, the catheters were removed and the artery was ligated to close the incision. The sham surgery (SM) group underwent femoral artery catheterization without blood loss. Following resuscitation for 2 h, the rats were administered LPS (cat. no., L2880; Sigma-Aldrich; Merck KGaA) at a dose of 100 µg/kg body weight ([@b16-etm-0-0-7757],[@b17-etm-0-0-7757]), which was intratracheally injected as the second 'hit' model of HS-LPS. During the entire experiment, all rats were under anesthesia.

The experiment was divided into two parts. The first part was used to confirm that pulmonary ECs participated in the inflammatory process subsequent to the second 'hit' and confirm whether the LPS-mediated upregulation of pyrin expression was impaired following HS. The rats were divided into 4 groups (n=6 for each group), as follows: i) A SM + tracheal injection of saline (SAL) group; this was the negative control group; ii) a HS + SAL group; iii) a SM + LPS group. with a tracheal injection of endotoxin; and iv) a HS + LPS group. A total of 8 h after tracheal injection, the rats were euthanized by administering an overdose of sodium pentobarbital solution (200 mg/kg) followed by cervical dislocation. Alveolar lavage was performed, lung tissues were collected and stored in liquid nitrogen, and then western blot analysis and immunofluorescence were performed.

The second part was performed to clarify the potential mechanism of the inhibition of the LPS-mediated upregulation of pyrin expression following HS. Rats were divided into four groups, as follows: i) A SM + LPS group; ii) a HS + LPS group (negative control group); ii) a HS + LPS + intratracheal injection of saline (NS) group; and iv) a HS + LPS + IL-10, with an intratracheal injection of recombinant IL-10 (BioLegend, Inc.) group. A total of 8 h after tracheal injection, the rats were euthanized by administering an overdose of sodium pentobarbital solution (200 mg/kg) followed by cervical dislocation. Alveolar lavage was performed, lung tissues were collected and stored in liquid nitrogen, and then western blot analysis was performed.

### Immunofluorescence

The lung tissues were fixed in 4% paraformaldehyde at 4°C overnight. The lung tissue of each group was serially sliced into 4-µm thick slices, and then incubated with 5% goat serum (Beyotime Institute of Biotechnology) at 22°C for 1 h. Lung tissues from each group were sliced into 2 sections, and each sample was incubated for 48 h at 4°C with cluster of differentiation (CD)34 mouse primary antibodies (cat. no., 60108-1-lg) and anti-pyrin rabbit primary antibodies (cat. no., 24280-1-AP; both 1:100; ProteinTech Group, Inc.) respectively. CD34, a cell surface sialomucin-like glycoprotein, is commonly used as a marker for identifying vascular ECs ([@b18-etm-0-0-7757]). Vascular ECs stained with CD34 exhibit a red color in the cytoplasm. PBS was used as blank control instead of the primary antibody. Subsequent to washing with PBS 3 times (3 min each), the slides were incubated with Cy3-conjugated goat anti-mouse immunoglobulin (Ig)G (cat. no., P0193) and FITC-conjugated goat anti-rabbit IgG (cat. no., P0186; both 1:100; Beyotime Institute of Biotechnology) for 1 h at room temperature. The staining method was performed according to the manufacturer\'s protocol of immunofluorescence kits (Immunol Fluorence Staining Kit with Cy3-Labeled Goat Anti-Mouse IgG and Immunol Fluorescence Staining Kit with FITC-Labeled Goat Anti-Rabbit IgG; both Beyotime Institute of Biotechnology). Images were obtained using a wide-field fluorescence microscope (Olympus X-cite 120; Olympus Corporation; magnification, ×200).

### Western blot analysis

Lung tissues of rats were homogenized on ice and lysed in lysis buffer which was prepared as follows: 10 mM Tris (pH 7.4), 5 mM EDTA, 150 mM NaCl, 10 mM NaF, 1% Triton X-100, 1 mM Na~3~VO~4~, 20 mM PMSF, 10 µg/ml leupeptin and 10 µg/ml aprotinin. The tissue homogenate was centrifuged at 1,000 × g in an Eppendorf centrifuge (Eppendorf) at 4°C for 10 min, and then the protein content in the supernatants were quantified using the Bradford method. Proteins (30 µg/lane) for each sample were separated using 10% SDS-PAGE gel and then transferred onto a polyvinylidene fluoride membrane. Subsequent to being blocked by 5% non-fat milk for 1 h at 22°C and then for 24 h at 4°C, the membranes were incubated with the primary antibodies against pyrin (1:1,000; cat. no., 24280-1-AP; ProteinTech Group, Inc.) and caspase-1 (1:2,000; cat. no., ab188326; Abcam). The blots were then washed and incubated with horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (1:2,000; cat. no., A0208; Beyotime Institute of Biotechnology) and HRP-labeled goat anti-mouse IgG (1:2,000; cat. no., A0216; Beyotime Institute of Biotechnology) for 2 h at room temperature. Protein bands were then detected by enhanced chemiluminescence. A ChemiDoc MP System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to capture the protein bands and then Image Lab 5.0 software (Bio-Rad Laboratories, Inc.) was used to analyze the bands. GAPDH and pro-caspase-1 were used as loading controls. Molecular weight standards were used from commercial markers (Thermo Fisher Scientific Inc.).

### Statistical analysis

SPSS v20.0 software (IBM Corp.) was applied for statistical analysis and the experiments were performed and repeated three times. Data are presented as the mean ± standard error of the mean. Data were analyzed using one-way analysis of variance followed by a Student-Neuman-Keuls post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### HS attenuates the LPS-induced pyrin expression in pulmonary vascular ECs

Subsequent to the removal of the majority of the macrophages following lung lavage, an analysis of the distribution of ECs and pyrin was performed. In immunofluorescence staining, cells stained with CD34 (red) were considered to be pulmonary vascular ECs. As presented in [Fig. 1](#f1-etm-0-0-7757){ref-type="fig"}, these CD34-positive cells presented a typical cobblestone-like morphology. Pyrin staining (green) demonstrated the presence of pyrin in ECs. The second *'*hit*'*, HS-LPS, substantially decreased the expression of pyrin protein in pulmonary vascular ECs. Furthermore, the expression of pyrin was evaluated in the supernatant of the lung homogenate ([Fig. 2A](#f2-etm-0-0-7757){ref-type="fig"}). No difference regarding the expression levels of pyrin between the SM + SAL group and the HS + SAL group was observed (P\>0.05). The expression levels of pyrin in the SM + LPS group were significantly increased in comparison with that in the SM + SAL group (P\<0.01), demonstrating that LPS stimulation had significantly increased the pyrin protein expression level in pulmonary vascular ECs. Additionally, the expression of pyrin was significantly increased in the HS + LPS group compared with the HS + SAL group (P\<0.01). However, the pyrin expression level in the HS + LPS group was significantly decreased compared with that of the SM + LPS group (P\<0.01), indicating that HS weakened the expression of pyrin induced by LPS.

As presented in [Fig. 2B](#f2-etm-0-0-7757){ref-type="fig"}, there was no significant difference with regard to the expression of caspase-1 in the SM + SAL and HS + SAL groups (P\>0.05). The expression of caspase-1 in the SM + LPS was increased compared with that in the SM + SAL group (P\<0.01), demonstrating that LPS stimulation increased the expression of caspase-1 protein in pulmonary vascular ECs. In addition, the expression of caspase-1 in the HS + LPS group was significantly increased compared with that in the SM + LPS group (P\<0.01). Collectively, HS augmented the LPS-induced caspase-1 expression.

### Involvement of IL-10 in regulating pyrin expression changes in pulmonary vascular ECs following the second 'hit' of HS-LPS

The expression of the pyrin protein is regulated by various cytokines, including IL-10 ([@b8-etm-0-0-7757]). The present study assessed the hypothesis that HS damaged the expression of IL-10, thereby affecting the expression of the pyrin protein, which resulted in the activation of caspase-1 subsequent to the second *'*hit*'* of HS-LPS. As presented in [Fig. 3A](#f3-etm-0-0-7757){ref-type="fig"}, the expression levels of pyrin in the SM + LPS group were significantly increased in comparison with the HS + LPS group (P\<0.01); and the expression levels of pyrin in the HS + LPS + IL-10 group were significantly increased compared with the HS + LPS group (P\<0.01). The results demonstrated that HS and the intratracheal injection of LPS may result in the expression of pyrin being significantly decreased, however, exogenous IL-10 treatment increases pyrin expression.

As presented in [Fig. 3B](#f3-etm-0-0-7757){ref-type="fig"}, the expression levels of cleaved caspase-1 were significantly different between the SM + LPS and HS + LPS groups (P\<0.01). The expression of caspase-1 was significantly decreased subsequent to IL-10 treatment compared with those in the HS + LPS group (P\<0.01). Although HS promoted the LPS-induced caspase-1 expression, intratracheal IL-10 treatment may decrease the expression of caspase-1, alleviating the inflammatory reaction. Therefore, the IL-10 treatment-inhibited caspase-1 activation induced by LPS may occur through the upregulation of pyrin expression in HS rats.

Discussion
==========

Systemic inflammatory response and organ failure are the primary factors affecting mortality in patients with HS and trauma. How HS enhances the inflammatory response of the body remains unclear. The activation of caspase-1 serves an important role in systemic inflammatory responses subsequent to shock ([@b10-etm-0-0-7757]). In the present study, it was revealed that LPS induced the activation of caspase-1 and also induced the expression of pyrin protein in pulmonary vascular ECs. The increase of pyrin protein expression may inhibit the activation of caspase-1 and form a negative feedback pathway. Notably, the increased expression of IL-10 induced by LPS in lung ECs may enhance the expression levels of pyrin in lung ECs and enhance the negative feedback regulation of inflammation. However, HS, by inhibiting the expression of IL-10, weakens the expression of pyrin, thereby damaging the negative feedback regulation of the inflammatory response and resulting in the enhancement of inflammatory body activation and consequently increasing the release of caspase-1.

The pyrin protein may inhibit the activation of caspase-1, and subsequently inhibit the maturation of inflammatory bodies. The destruction of the C terminal of the pyrin protein may enhance the sensitivity of mice to endotoxins and increase the activation of caspase-1, which indicates that the pyrin protein serves an important role in the maturation of inflammatory bodies ([@b19-etm-0-0-7757]). The pyrin protein interacts with caspase-1, apoptosis-associated speck-like protein containing a CARD, NLR family pyrin domain containing (NLRP)1, NLRP2, NLRP3 and IL-1B (precursors of inflammatory components) through its SPIa/ryanodine receptor and pyrin structural domains, thereby functioning as an inhibitor of the inflammatory body ([@b20-etm-0-0-7757]). A previous study has demonstrated that pyrin mutations may result in the activation of the NLRP3 independent inflammatory body, causing autoimmune diseases ([@b21-etm-0-0-7757]). The present study suggested that pyrin may result in different inflammatory outcomes through multiple different pathways.

IL-10 serves an important role in limiting inflammation and maintaining immune homeostasis ([@b22-etm-0-0-7757]). In acute respiratory distress syndrome, IL-10 has been demonstrated to inhibit proinflammatory mediators produced by pulmonary macrophages ([@b23-etm-0-0-7757]). In a previous clinical study, patients with acute respiratory distress syndrome, but with low levels of circulating and alveolar lavage fluid IL-10 exhibited an increased mortality rate compared with those with high IL-10 levels ([@b24-etm-0-0-7757]). At the gene level, a previous study indicated that, compared with pure LPS stimulation, hemorrhagic shock combined with LPS may significantly decrease the transcription of IL-10 mRNA ([@b25-etm-0-0-7757]). Patients that succumbed to mortality due to sepsis exhibited a decrease in IL-10 secretion ([@b26-etm-0-0-7757]), indicating that exogenous IL-10 had protective effects in sepsis or acute pancreatitis models ([@b26-etm-0-0-7757],[@b27-etm-0-0-7757]). A limitation of the present study is the absence of an *in vitro* model. A previous study confirmed that an *in vitro* HS model inhibited the LPS-induced increase of IL-10 expression at the gene level, which is closely associated with the progression of HS-induced pulmonary inflammation ([@b28-etm-0-0-7757]). It has been suggested that pyrin may serve an inhibitory role in casepase-1 activation and inhibit the development of inflammation ([@b29-etm-0-0-7757],[@b30-etm-0-0-7757]). In the present study, it was revealed that IL-10 may inhibit the activation of inflammatory cells by inducing the expression of pyrin in pulmonary vascular ECs. It was also confirmed that LPS induced the IL-10-based upregulated pyrin expression in lung ECs. The LPS treatment that induced pyrin protein expression in pulmonary vascular ECs was weakened by HS and LPS in the second 'hit' model. However, exogenous IL-10 may reverse the inhibition of pyrin expression in HS. It was additionally confirmed that in pulmonary vascular ECs, IL-10 was able to inhibit HS in a rat model of LPS-induced caspase-1 activation in the lungs, and the data from the present study revealed that in pulmonary vascular ECs, the expression of IL-10 may induce pyrin, while decreasing the activation of the inflammasome, thereby serving an important role in lung injury that occurs subsequent to HS. Furthermore, the present study had certain limitations: In addition to those aforementioned, only exogenous IL-10 was used, and the results obtained were used to examine our hypothesis. Due to the lack of measurement of the other endogenous dynamic changes following HS in this experiment, the association between pyrin and endogenous IL-10 requires additional verification.

In conclusion, it was proposed that HS attenuated the LPS-induced pyrin expression in pulmonary vascular ECs and that HS may also damage the expression of IL-10, thereby decreasing the expression of the pyrin protein in pulmonary vascular ECs, resulting in the activation of caspase-1 following the second LPS 'hit'. Additional studies investigating the expression changes and mechanism of pyrin in pulmonary vascular ECs are required to identify the underlying mechanism of SIRS induced by HS and novel targets for clinical intervention.
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![HS attenuates the LPS-induced pyrin expression in pulmonary vascular ECs. Immunofluorescence staining analysis was conducted. Pulmonary vascular endothelial cells (white arrows) were incubated with anti-CD34 and anti-pyrin antibodies. The CD34-positive cells (red) presented a typical cobblestone-like morphology. The merged images (yellow) demonstrate overlap of pyrin (green) and CD34 (red). Magnfication, ×200. SM, sham operation; SAL, tracheal injection of saline; HS, hemorrhagic shock; LPS, tracheal injection of lipopolysaccharide. CD34, cluster of differentiation 34.](etm-18-03-1768-g00){#f1-etm-0-0-7757}

![HS leads to a downregulation and upregulation LPS-induced pyrin and caspase-1 expression, respectively, in pulmonary vascular ECs. Western blot analysis was conducted. Expression changes of (A) pyrin and (B) caspase-1 following HS-LPS 'hit'. \*P\<0.05 vs. the SM + SAL group. ^\#^P\<0.05 vs. the HS + SAL group. ^Δ^P\<0.05 vs. the SM + LPS group (n=6). SM, sham operation; SAL, tracheal injection of saline; HS, hemorrhagic shock; LPS, tracheal injection of lipopolysaccharide.](etm-18-03-1768-g01){#f2-etm-0-0-7757}

![Involvement of IL-10 in regulating pyrin expression changes in pulmonary vascular ECs following the second 'hit' of HS-LPS. Western blot analysis was conducted. (A) Expression changes of pyrin following HS-LPS 'hit' and exogenous recombinant IL-10 treatment. \*P\<0.05 vs. HS + LPS group. ^\#^P\<0.05 vs. HS + LPS group. ^Δ^P\<0.05 vs. HS + LPS + NS group (n=6). (B) Expression changes of caspase-1 following HS-LPS 'hit' and exogenous recombinant IL-10 treatment. \*P\<0.05 vs. SM + LPS group. ^\#^P\<0.05 vs. HS + LPS group. ^Δ^P\<0.05 vs. HS + LPS + NS group (n=6). SM, sham operation; NS, intratracheal injection of saline; HS, hemorrhagic shock; LPS, tracheal injection of lipopolysaccharide; IL-10, interleukin-10.](etm-18-03-1768-g02){#f3-etm-0-0-7757}
